Status:
UNKNOWN
Immunisation for Adolescents Against Serious Communicable Diseases (B Part of it NT)
Lead Sponsor:
University of Adelaide
Collaborating Sponsors:
The University of New South Wales
Menzies School of Health Research
Conditions:
Gonorrhea
Meningococcal Disease
Eligibility:
All Genders
14-19 years
Brief Summary
This study aims to implement a targeted 4CMenB immunisation program in young people aged 14-19 years in the Northern Territory (NT). As part of the NT program consenting 14-19 year olds will receive 2...
Detailed Description
Meningococcal disease and gonorrhea cause severe morbidity in Australian adolescents, particularly among Aboriginal People. The two diseases are caused by bacteria that are genetically related, but ve...
Eligibility Criteria
Inclusion
- All consenting 14-19 year olds residing in the Northern Territory in 2020-2021
Exclusion
- Anaphylaxis following any component of Bexsero® vaccine
- Previous receipt of MenB vaccine (Bexsero® (Previous receipt of MenNZBTM is allowed).
- Known pregnancy
- Clinical conditions representing a contraindication to intramuscular vaccination and venipuncture
- Any clinical condition that, in the opinion of the investigator, might pose additional risk to the subject due to participation in the study
Key Trial Info
Start Date :
March 4 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2024
Estimated Enrollment :
7100 Patients enrolled
Trial Details
Trial ID
NCT04398849
Start Date
March 4 2021
End Date
December 31 2024
Last Update
March 9 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Northern Territory
Central Australia, Australia